Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study.

Thomas Bachelot,José Ángel García-Sáenz,Sunil Verma,Maya Gutierrez,Xavier Pivot,Mark Kozloff,Catherine Prady,Xin Huang,Reza Khosravan,Zhixiao Wang,Rossano Cesari,Vanessa Tassell,Kenneth A. Kern,Jean-Yves Blay,Ana Lluch

Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study.

2014

Thomas Bachelot
José Ángel García-Sáenz
Sunil Verma
Maya Gutierrez
Xavier Pivot
Mark Kozloff
Catherine Prady
Xin Huang
Reza Khosravan
Zhixiao Wang
Rossano Cesari
Vanessa Tassell
Kenneth A. Kern
Jean-Yves Blay
Ana Lluch

Background This phase II study evaluated the efficacy and safety/tolerability of sunitinib plus trastuzumab in patients with HER2-positive advanced breast cancer (ABC).

Keywords:

Pathology
Breast cancer
Cancer research
Trastuzumab
Phases of clinical research
Surgical oncology
Medicine
Sunitinib
Tolerability
in patient
advanced breast
Cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations